Research is integral to the work of the American Liver Foundation and is essential to improving, treating and finding a cure for liver disease. Since 1979, the Research Awards Program has provided more than $26 million in research funding to over 850 scientists and physicians pursuing careers in liver disease research and treatment.
ALF’s Liver Scholar Award is a three-year basic science award that encourages young investigators to pursue a career in liver-related research.
Our Post-Doctoral Research Fellowship Award is a one-year award support for MD, PhD and MD/PhD postdoctoral fellows seeking professional development and experience in liver research.
Our Distinguished Scientific Achievement Award honors a scientist who has made a major contribution to liver disease research in basic science or in its application towards the prevention, treatment or cure of liver disease.
ALF’s National Toll-Free Helpline, 1-800-GO-LIVER, fields 10,000 inquiries each year via phone, email and live chat. Interpretation services are available for 189 languages and dialects. More inquiries come from Florida each year than any other state except California.
Our online and in-person support communities provide people with both peer-to-peer and social worker-led support.
While ALF does not endorse or recommend any individual providers, people can find liver disease specialists, estimate costs, and book appointments through our website. They can also find clinical trials that might be appropriate for them.
ALF is on a mission to educate the public about the liver.
Our webinar series is designed to inform patients and caregivers about different types of liver disease. It allows people to engage with expert clinicians and patient advocates via interactive question and answer sessions.
ALF’s core community programs, Love Your Liver and Liver Wellness, are offered by our 16 regional divisions and provide age-appropriate overviews of how to maintain good liver health. Our most popular program, Viral Hepatitis, targets those at highest risk of hepatitis A, B, or C. In 2017, ALF introduced two new community-based programs: Alcohol and Your Liver and The ABC’s of Non-Alcoholic Fatty Liver Disease.
For patients who emerge from doctor visits with additional questions, our “Ask the Experts” series fills critical information gaps. In 2017, ALF held these programs in more than 20 cities.
Our print and online educational materials on over 30 liver topics are available at no cost and have been translated into Spanish, Chinese, Korean, Vietnamese and Russian.
Two of ALF’s recent public awareness campaigns focused on liver cancer and hepatitis C. Our annual “Are you at risk?” campaign, which encourages people to learn their risk of liver cancer, was seen by nearly 230 million people in 2017. Our hepatitis C campaign focused on veterans since they are three times more likely to be infected than people who have never served in the military.
Enhancing the clinical practice of healthcare providers through online and in-person medical education ultimately supports patients – by improving their care and health outcomes. ALF brings doctors together for academic debates, disease-specific conferences, research-focused symposia, webinars and more to advance their knowledge, improve their efficiency and help to build professional alliances.
ALF serves as a trusted voice for individuals with compromised livers. We testify before Congress, state and local legislatures both on our annual “Hill Day” and throughout the year to help effect change in public health policy, including: improved patient access to treatment; expanded public health education; greater funding for research; and support for increases in organ donation and organ donor awareness.
ALF’s National Patient Advisory Committee (NPAC) advocates for liver patients, raises awareness through traditional and social media, and helps to guide our communication activities. We currently have cohorts for: hepatitis C; primary biliary cholangitis; acute alcohol-related hepatitis; hepatic encephalopathy; and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Our regional divisions are engaged with coalitions and task forces that are educating patients, medical professionals and the public about specific diseases and health epidemics.